Brandon Capital

OncoRes Medical Pty Ltd is an early-stage medical device company based in Nedlands, Australia, founded in 2014. The company specializes in developing a patented imaging technology that provides surgeons with real-time, micro-scale images of tissue stiffness and elasticity during breast cancer surgeries. This innovative tool integrates optical coherence tomography to enhance surgical accuracy, aiding in the differentiation between tumor and healthy tissue. OncoRes collaborates with leading researchers at the University of Western Australia and the Harry Perkins Institute of Medical Research, as well as breast cancer surgeons in the Western Australian public health system. With support from the Medical Research Commercialisation Fund, OncoRes Medical aims to improve clinical applications by enabling precise intraoperative assessments of tissue microstructure, ultimately striving to transform the standard of care in breast cancer treatment.

Ankere is striving to develop transformative therapies based on excellent science that will enable people to live long and healthy lives.

Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States.

Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.

Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.

Myricx Bio is a drug discovery company based in Stevenage, United Kingdom, that specializes in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT). Founded in 2019, the company focuses primarily on oncology while also exploring applications in other diseases such as inflammatory conditions, epilepsy, and Alzheimer’s disease. By targeting N-myristoyl transferase, Myricx Bio aims to unlock new therapeutic potentials, providing precision medicines that can specifically kill cancer cells and address viral infections. Through its innovative approach, the company seeks to deliver effective treatments for a diverse range of health conditions.

Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.

Denteric is developing a vaccine based on research conducted at the University of Melbourne, with collaborative support from CSL Limited, to fight the disease and will receive the money in three parts each year from 2019 to 2021.

EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.

Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States.

Q-Sera technology aims to accelerate the clotting of blood to more rapidly produce high quality serum in blood clotting tubes. Q-Sera Pty Ltd uses the coagulant properties of snake venom-derived proteins to develop blood collection tubes that rapidly produce high quality serum. Australian scientists have found a way to use components of snake venom to improve an essential clinical tool which will assist in optimising laboratory efficiency, clinical diagnosis and patient care. The venom of some snakes (including the Australian Taipan) has a potent ability to coagulate the blood of mammals including humans and it is this ability which caught the interest of a group of Queensland medical scientists and pathologists. The team isolated the potent clotting proteins and used them to develop superior blood collection tubes.

Global Kinetics Corporation develops mobile health technology aimed at improving the management of patients with Parkinson's disease and other movement disorders. Founded in 2007 and based in Melbourne, Australia, the company focuses on creating tools for the monitoring, quantification, and reporting of movement symptoms associated with neurological diseases. One of its key products is the PKG Data Logger, a wrist-worn device that automatically records movement data, assisting healthcare professionals in diagnosing and treating movement disorders. The technology was initially developed by Professor Malcolm Horne and Dr. Rob Griffiths at the Florey Institute of Neuroscience & Mental Health, Australia's largest neuroscience research team.

Okogen, Inc. is a biotechnology company based in Encinitas, California, focused on developing therapeutics for ocular infections affecting both adults and children. The company aims to address unmet needs in the treatment of infectious ocular diseases, particularly where current therapies are inadequate or unavailable. Its lead candidate, OKG-0301, is a potent antiviral that targets viral replication intracellularly, specifically designed to combat adenoviral infections of the eye and other ocular viruses such as herpes simplex virus, varicella-zoster virus, and picornavirus. Through its innovative platform, Okogen strives to reduce patient suffering, enhance quality of life, and preserve vision for those affected by these conditions. Founded in 2015, the company is dedicated to advancing ocular health through its specialized research and development efforts.

EBR Systems, Inc. is focused on developing innovative implantable devices for cardiac rhythm management, specifically aimed at treating patients with heart failure and cardiac arrhythmias. The company's flagship product, the Wireless Cardiac Stimulation of the Left Ventricle System, utilizes proprietary wireless technology to provide endocardial pacing for cardiac resynchronization therapy. This approach enhances the heart's pumping efficiency by synchronizing the contractions of the left and right ventricles. Founded in 2003 and headquartered in Sunnyvale, California, EBR Systems is committed to advancing therapeutic options for patients suffering from cardiac rhythm diseases through its novel technologies.

QUE Oncology, Inc. is a biotechnology company based in Atlanta, Georgia, founded in 2013 through a collaboration between Emory University and The University of Queensland's research commercialization company, UniQuest. The company focuses on developing innovative drug therapies for cancer, particularly breast and prostate cancer, by licensing intellectual property from both institutions. QUE's leading drug candidate, Q-122, is currently in Phase 1b clinical development and targets hot flashes in women undergoing anti-estrogen therapy for breast cancer. This compound is a non-hormonal, orally bioavailable small molecule designed to alleviate moderate to severe vasomotor symptoms, including night sweats. QUE Oncology's research pipeline also encompasses projects related to prostate cancer, melanoma, and cancer pain, aiming to meet significant unmet medical needs in oncology.

Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.

MecRx is a drug development company that works on new treatments for cancer and novel mechanism of action antibiotics. Using proprietary “hit identification” technology, MecRx is developing inhibitors of cMyc, a protein that is deregulated in over 50% of all human cancers. MecRx draws on the expertise of the Peter MacCallum Cancer Centre and CSIRO and is headquartered in Melbourne, Australia. MecRx was founded in 2013 by an ex-pharma/biotech team. MecRx is run as a virtual company based in Melbourne, Australia and its shareholders and service providers include the Peter MacCallum Cancer Institute and CSIRO. The company secured $5m Series A investment from the MRCF (www.mrcf.com.au) and CSIRO in 2015.

Elastagen Pty Ltd., a clinical stage medical company, produces and sells products based on the human protein tropoelastin. The company offers injectable dermoaesthetic products, stretch mark products, scar revision and wound healing products, and sealant and osteoskeletal products for applications areas, including skin rejuvenation, scar remodeling, and tissue repair. It sells its products through online orders. Elastagen Pty Ltd. was founded in 2003 and is based in Eveleigh, Australia with production operations in Europe; and clinical operations in the United Kingdom. As of April 6, 2018, Elastagen Pty Ltd. operates as a subsidiary of Allergan plc.

Cardiora Pty Ltd. is a clinical stage biopharmaceutical company based in Melbourne, Australia, founded in 2015. The company focuses on developing innovative treatments for patients suffering from end-stage heart failure, a condition characterized by high mortality rates and frequent hospital admissions. Cardiora's lead product, CRD-102, is an oral medication specifically designed for this patient population. As of now, the company is conducting Phase Ib trials and completing IND enabling studies, with plans to advance into Phase II trials. Through its research and development efforts, Cardiora aims to improve the quality of life for individuals facing this serious health challenge.

Aravax Pty Ltd. is a biotechnology company based in Melbourne, Australia, dedicated to developing innovative treatments for peanut allergies. Founded in 2015 through the acquisition of intellectual property from Alfred Health and Monash University, Aravax aims to create the first safe and effective treatment for this condition. The company is focused on utilizing its proprietary technology to reset the immune system, allowing patients to tolerate peanuts without experiencing allergic reactions during treatment. By developing vaccines designed to eliminate the risk of life-threatening reactions, Aravax seeks to improve the quality of life for individuals with peanut allergies, addressing symptoms such as mild itchiness, rash, and gastrointestinal upset.

MetaBloQ Pty Ltd is a biotechnology company based in Melbourne, Australia, specializing in the development of innovative drugs aimed at treating challenging cancers, including triple-negative breast cancer, prostate cancer, and melanoma. Founded in 2016, the company focuses on discovering and developing therapies that target specific metabolic processes within cancer cells, with the goal of minimizing toxicity to non-cancerous cells. Through its research and development efforts, MetaBloQ aims to provide patients with safer and more effective treatment options, enhancing their overall quality of life during cancer therapy.

Global Kinetics Corporation develops mobile health technology aimed at improving the management of patients with Parkinson's disease and other movement disorders. Founded in 2007 and based in Melbourne, Australia, the company focuses on creating tools for the monitoring, quantification, and reporting of movement symptoms associated with neurological diseases. One of its key products is the PKG Data Logger, a wrist-worn device that automatically records movement data, assisting healthcare professionals in diagnosing and treating movement disorders. The technology was initially developed by Professor Malcolm Horne and Dr. Rob Griffiths at the Florey Institute of Neuroscience & Mental Health, Australia's largest neuroscience research team.

OccuRx Pty. Ltd. is a Melbourne-based biopharmaceutical company focused on developing innovative therapeutic strategies for treating ophthalmic disorders linked to retinal fibrosis and inflammation. Established in 2014, the company has a library of proprietary small-molecule drugs designed to address the unmet clinical needs in ocular therapies, particularly for conditions like diabetic retinopathy and other fibrotic diseases of the retina. These therapeutic approaches aim to enhance visual acuity and prevent vision loss by targeting the growth of abnormal blood vessels and reducing inflammation in retinal neurons. OccuRx's work is supported by funding from prominent investors, including the Medical Research Commercialisation Fund and Brandon Capital Partners.

Solvanix Pty Ltd. is a biotechnology company based in Darlinghurst, Australia, that specializes in enhancing the stability and reducing the aggregation of fully human antibodies. Established in 2014, the company has developed proprietary technology known as StAbilize, which effectively boosts the stability of monoclonal antibodies, antibody fragments, and bi-specifics. This innovation addresses the common challenges faced by traditional antibodies, such as limited stability and a tendency to aggregate, which can adversely affect manufacturability and product quality. Solvanix collaborates with partners in the biotechnology and pharmaceutical industries to refine their therapeutic antibodies, offering both commercial and non-exclusive licenses for its StAbilize technology.

Heart Metabolics Limited is focused on developing a pharmaceutical therapy for hypertrophic cardiomyopathy (HCM), a condition characterized by the thickening of the heart muscle, which can lead to heart failure and sudden death. With over 100,000 cases in the United States, HCM often presents more severely in younger individuals, particularly athletes. While existing cardiovascular drugs offer some relief, many patients do not benefit from current treatments. Heart Metabolics is advancing perhexiline, a drug already approved in Australia and New Zealand for angina, as a potential therapy for all forms of HCM. Following encouraging results from phase II clinical trials, the company is preparing to conduct further clinical trials in the U.S. and aims to obtain FDA approval for perhexiline as an orphan drug, a designation it already holds. Through this development, Heart Metabolics seeks to address significant unmet medical needs in HCM treatment.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Protego Medical Pty Ltd is a medical technology company based in Melbourne, Australia, founded in 2013. The company specializes in developing a device designed to provide sternal protection during cardiac surgery, aiming to enhance patient safety and surgical outcomes.

Auspherix Pty Ltd. is an early-stage anti-infectives company based in Stevenage, United Kingdom, focused on the discovery and development of organogold-based antibiotics aimed at treating serious and challenging infections that may be life-threatening. Established in 2013, the company is working to advance its novel antibiotic candidates through pre-clinical and clinical development stages. To facilitate this progress, Auspherix is seeking additional investment and industry partnerships to support the broad-spectrum application of its innovative therapies.

PolyActiva Pty Ltd is an Australian company focused on developing therapeutic products for ocular diseases and other medical applications. Established in 2009 and based in Melbourne, with a laboratory in Parkville, the company utilizes proprietary drug-polymer conjugate technology to facilitate site-specific drug delivery through various medical device components, including ocular implants and drug-eluting fibers. PolyActiva's product offerings include latanoprost ocular implants designed for glaucoma treatment and levofloxacin ocular implants aimed at preventing endophthalmitis after ocular surgery, as well as programs targeting anti-inflammatory treatments.

G I Therapies develops an innovative non-invasive medical device for the treatment of chronic constipation (CC) in adults and children. GI Therapies was established in Melbourne in 2012 to commercialise innovative technology the treat gastrointestinal motility disorders including chronic constipation, irritable bowel syndrome with constipation and gastroparesis.

Q-Sera technology aims to accelerate the clotting of blood to more rapidly produce high quality serum in blood clotting tubes. Q-Sera Pty Ltd uses the coagulant properties of snake venom-derived proteins to develop blood collection tubes that rapidly produce high quality serum. Australian scientists have found a way to use components of snake venom to improve an essential clinical tool which will assist in optimising laboratory efficiency, clinical diagnosis and patient care. The venom of some snakes (including the Australian Taipan) has a potent ability to coagulate the blood of mammals including humans and it is this ability which caught the interest of a group of Queensland medical scientists and pathologists. The team isolated the potent clotting proteins and used them to develop superior blood collection tubes.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Vaxxas Pty. Ltd. is an Australian company that specializes in the development and commercialization of innovative vaccine delivery technologies. Established in 2011 and headquartered in Sydney, with an additional office in Cambridge, Massachusetts, Vaxxas focuses on a needle-free delivery system known as the Nanopatch. This system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin, allowing for direct deposition of vaccines among a high concentration of immune cells. By targeting these immunological cells, Vaxxas aims to enhance the activation of the immune system and improve vaccine efficacy, thereby transforming the global landscape of vaccine administration.

Signostics Limited is a medical technology company based in Clovelly Park, Australia, that specializes in the development and manufacture of portable point-of-care devices for both medical and veterinary markets. The company's flagship products include the SignosRT Bladder Scanner, which utilizes ultrasound technology to detect the bladder and calculate its volume, and the SignosRT Handheld Ultrasound, designed to assist clinicians in their examinations. These devices cater to a variety of applications, including hospital medicine, family practice, remote healthcare, and physical therapy. Established in 2005, Signostics has expanded its reach internationally, with regulatory approvals for its products in the United States, Europe, and Australia. The company also maintains offices in Palo Alto, California, and continues to focus on delivering innovative and accessible medical solutions through a network of global distributors.

Signostics Limited is a medical technology company based in Clovelly Park, Australia, that specializes in the development and manufacture of portable point-of-care devices for both medical and veterinary markets. The company's flagship products include the SignosRT Bladder Scanner, which utilizes ultrasound technology to detect the bladder and calculate its volume, and the SignosRT Handheld Ultrasound, designed to assist clinicians in their examinations. These devices cater to a variety of applications, including hospital medicine, family practice, remote healthcare, and physical therapy. Established in 2005, Signostics has expanded its reach internationally, with regulatory approvals for its products in the United States, Europe, and Australia. The company also maintains offices in Palo Alto, California, and continues to focus on delivering innovative and accessible medical solutions through a network of global distributors.

Fibrotech Therapeutics develops and offers novel drug candidates for the treatment of fibrosis in chronic conditions. It develops drugs for kidney diseases, diabetics, heart failure, pulmonary fibrosis, and arthritis. Founded in 2006, Fibrotech Therapeutics is based in Wonga Park, Australia.